Multidrug resistance-associated protein 2
| ABCC2 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | ABCC2, ABC30, CMOAT, DJS, MRP2, cMRP, Multidrug resistance-associated protein 2, ATP binding cassette subfamily C member 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 601107; MGI: 1352447; HomoloGene: 68052; GeneCards: ABCC2; OMA:ABCC2 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Multidrug resistance-associated protein 2 (MRP2) also called canalicular multispecific organic anion transporter 1 (cMOAT) or ATP-binding cassette sub-family C member 2 (ABCC2) is a protein that in humans is encoded by the ABCC2 gene.[5][6][7]
Function
MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). More specifically, this protein is a member of the MRP subfamily, which is involved in multi-drug resistance. This protein is expressed in the canalicular (apical) part of the hepatocyte and functions in biliary transport. Substrates include anticancer drugs such as vinblastine; therefore, this protein appears to contribute to drug resistance in mammalian cells.
MRP2 is also expressed in the apical membrane of proximal renal tubule endothelial cells where they are involved in the excretion of small organic anions.[8]
MRP2 inhibitors
| Drug | Class | Indications | Source | Structure |
|---|---|---|---|---|
| probenecid | uricosuric | gout hyperuricemia |
[9] | 
|
| furosemide | loop diuretic | heart failure edema |
[9] | 
|
| ritonavir | protease inhibitor | antiretroviral | [10] | 
|
| saquinavir | protease inhibitor | antiretroviral | [11] | 
|
| lamivudine | Nucleoside analog | antiviral | [12] | 
|
| abacavir | Nucleoside analog | antiretroviral | [12] | 
|
| emtricitabine | Nucleoside analog | antiviral | [12] | 
|
| efavirenz | NNRTI | antiretroviral | [12] | 
|
| delavirdine | NNRTI | antiretroviral | [12] | 
|
| nevirapine | NNRTI | antiretroviral | [12] | 
|
| cidofovir | nucleoside phosphonate | antiviral | [13] | 
|
| adefovir | nucleoside phosphonate | antiviral | [11] | 
|
| tenofovir | nucleoside phosphonate | antiviral | [12] | 
|
Clinical significance
Dubin–Johnson syndrome
Several different mutations in this gene have been observed in patients with Dubin–Johnson syndrome (DJS), an autosomal recessive disorder characterized by conjugated hyperbilirubinemia.[7][14]
Iatrogenic Fanconi syndrome
Many negatively charged metabolic waste products are eliminated from the body by the kidneys. These organic anions are transported from the blood into the endothelial cells of the renal proximal tubules by the OAT1 transporter. From there, these waste molecules are transported into the lumen of the tubule by the MRP2 transporter. Many drugs are eliminated from the body by this mechanism. Some of these drugs pass through the MRP2 transporter slowly. This may cause a buildup of organic anions in the cytoplasm of the cells.
Drugs that inhibit the MRP2 transporter can cause a buildup of organic anions inside renal proximal tubule cells. If some of these organic anions inhibit mitochondrial DNA synthesis, it may cause iatrogenic Fanconi syndrome. The nucleoside phosphonate adefovir is a MRP2 inhibitor that has been linked to kidney disease.[15] Tenofovir[16] and cidofovir[17] are also nucleoside phosphonates that inhibit MRP2 and have been associated with Fanconi syndrome.
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
Irinotecan Pathway edit
- ^ The interactive pathway map can be edited at WikiPathways: "IrinotecanPathway_WP229".
See also
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000023839 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025194 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, et al. (September 1996). "A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation". Cancer Research. 56 (18): 4124–4129. PMID 8797578.
- ^ van Kuijck MA, Kool M, Merkx GF, Geurts van Kessel A, Bindels RJ, Deen PM, et al. (Sep 1997). "Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization". Cytogenetics and Cell Genetics. 77 (3–4): 285–287. doi:10.1159/000134599. PMID 9284939. S2CID 46739365.
- ^ a b "Entrez Gene: ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2".
- ^ Sekine T, Miyazaki H, Endou H (February 2006). "Molecular physiology of renal organic anion transporters". American Journal of Physiology. Renal Physiology. 290 (2): F251 – F261. doi:10.1152/ajprenal.00439.2004. PMID 16403838.
- ^ a b Bakos E, Evers R, Sinkó E, Váradi A, Borst P, Sarkadi B (April 2000). "Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions". Molecular Pharmacology. 57 (4): 760–768. doi:10.1124/mol.57.4.760. PMID 10727523.
- ^ Peyrière H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. (March 2004). "Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases". Journal of Acquired Immune Deficiency Syndromes. 35 (3): 269–273. doi:10.1097/00126334-200403010-00007. PMID 15076241.
- ^ a b Gimenez F, Fernandez C, Mabondzo A (June 2004). "Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins". Journal of Acquired Immune Deficiency Syndromes. 36 (2): 649–658. doi:10.1097/00126334-200406010-00001. PMID 15167283. S2CID 6030800.
- ^ a b c d e f g Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE (March 2007). "Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors". Drug Metabolism and Disposition. 35 (3): 340–344. doi:10.1124/dmd.106.012765. PMID 17172311. S2CID 46141353.
- ^ Miller DS (November 2001). "Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule". The Journal of Pharmacology and Experimental Therapeutics. 299 (2): 567–574. doi:10.1016/S0022-3565(24)29264-8. PMID 11602668.
- ^ Morii K, Yamamoto T (July 2016). "IMAGES IN CLINICAL MEDICINE. Dubin-Johnson Syndrome". The New England Journal of Medicine. 375 (1): e1. doi:10.1056/nejmicm1509529. PMID 27406372.
- ^ Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. (February 2003). "Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B". The New England Journal of Medicine. 348 (9): 808–816. doi:10.1056/NEJMoa020681. PMID 12606735.
- ^ Atta MG, Fine DM (March 2009). "Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice". The AIDS Reader. 19 (3): 118–119. PMID 19334329.
- ^ Vittecoq D, Dumitrescu L, Beaufils H, Deray G (August 1997). "Fanconi syndrome associated with cidofovir therapy". Antimicrobial Agents and Chemotherapy. 41 (8): 1846. doi:10.1128/AAC.41.8.1846. PMC 164022. PMID 9257778.
Further reading
- Keppler D, König J (2001). "Hepatic secretion of conjugated drugs and endogenous substances". Seminars in Liver Disease. 20 (3): 265–272. doi:10.1055/s-2000-9391. PMID 11076395. S2CID 25626705.
- Gerk PM, Vore M (August 2002). "Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition". The Journal of Pharmacology and Experimental Therapeutics. 302 (2): 407–415. doi:10.1124/jpet.102.035014. PMID 12130697. S2CID 873234.
- Mayer R, Kartenbeck J, Büchler M, Jedlitschky G, Leier I, Keppler D (October 1995). "Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes". The Journal of Cell Biology. 131 (1): 137–150. doi:10.1083/jcb.131.1.137. PMC 2120605. PMID 7559771.
- Büchler M, König J, Brom M, Kartenbeck J, Spring H, Horie T, et al. (June 1996). "cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats". The Journal of Biological Chemistry. 271 (25): 15091–15098. Bibcode:1996JBiCh.27115091B. doi:10.1074/jbc.271.25.15091. PMID 8662992.
- Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, et al. (June 1997). "A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome". Hepatology. 25 (6): 1539–1542. doi:10.1002/hep.510250635. PMID 9185779. S2CID 22635775.
- Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, et al. (February 1998). "Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome". Human Molecular Genetics. 7 (2): 203–207. doi:10.1093/hmg/7.2.203. PMID 9425227.
- Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, et al. (April 1998). "Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA". The Journal of Clinical Investigation. 101 (7): 1310–1319. doi:10.1172/JCI119886. PMC 508708. PMID 9525973.
- Kajihara S, Hisatomi A, Mizuta T, Hara T, Ozaki I, Wada I, et al. (December 1998). "A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome". Biochemical and Biophysical Research Communications. 253 (2): 454–457. Bibcode:1998BBRC..253..454K. doi:10.1006/bbrc.1998.9780. PMID 9878557.
- Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, et al. (March 1999). "Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome". American Journal of Human Genetics. 64 (3): 739–746. doi:10.1086/302292. PMC 1377791. PMID 10053008.
- Schaub TP, Kartenbeck J, König J, Spring H, Dörsam J, Staehler G, et al. (June 1999). "Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma". Journal of the American Society of Nephrology. 10 (6): 1159–1169. doi:10.1681/ASN.V1061159. PMID 10361853.
- Tsujii H, König J, Rost D, Stöckel B, Leuschner U, Keppler D (September 1999). "Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome". Gastroenterology. 117 (3): 653–660. doi:10.1016/S0016-5085(99)70459-2. PMID 10464142.
- Kocher O, Comella N, Gilchrist A, Pal R, Tognazzi K, Brown LF, et al. (September 1999). "PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein". Laboratory Investigation; A Journal of Technical Methods and Pathology. 79 (9): 1161–1170. PMID 10496535.
- Tanaka T, Uchiumi T, Hinoshita E, Inokuchi A, Toh S, Wada M, et al. (December 1999). "The human multidrug resistance protein 2 gene: functional characterization of the 5'-flanking region and expression in hepatic cells". Hepatology. 30 (6): 1507–1512. doi:10.1002/hep.510300617. PMID 10573531. S2CID 22514353.
- St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, et al. (October 2000). "Expression of members of the multidrug resistance protein family in human term placenta". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 279 (4): R1495 – R1503. doi:10.1152/ajpregu.2000.279.4.R1495. PMID 11004020. S2CID 36043361.
- Keitel V, Kartenbeck J, Nies AT, Spring H, Brom M, Keppler D (December 2000). "Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome". Hepatology. 32 (6): 1317–1328. doi:10.1053/jhep.2000.19791. PMID 11093739. S2CID 20920288.
- Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K (March 2001). "Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects". Pharmacogenetics. 11 (2): 175–184. doi:10.1097/00008571-200103000-00008. PMID 11266082.
- Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U (October 2001). "Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome". The Journal of Biological Chemistry. 276 (40): 36923–36930. Bibcode:2001JBiCh.27636923M. doi:10.1074/jbc.M105047200. PMID 11477083.
- Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P (2005). "Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 35 (10–11): 1055–1066. doi:10.1080/00498250500354493. PMID 16393861. S2CID 6888528.
External links
- ABCC2+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
This article incorporates text from the United States National Library of Medicine, which is in the public domain.